Baxter International Inc.
BAXHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 17, 2026
Scan Results
Daily timeframeBaxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The $12.06B market capitalization puts BAX squarely in large-cap range for its industry. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Market Cap
$12.06B
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
11.64
EPS (TTM)
$-2.01
EPS (Fwd)
$2.01
ROE
-15.0%
ROA
2.9%
Cash
$2.02B
Total Debt
$9.69B
Free CF
$900.9M
52W Change
-16.3%
Annual Financials
Cash vs Debt
Baxter International Inc. carries $9.69B in total debt against $2.02B in cash reserves — debt is roughly 4.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $900.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -15.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.9% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $10.06B to $11.24B.
BAX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BAX.